• Publications
  • Influence
Thalidomide: a review of approved and investigational uses.
Use of thalidomide is limited by toxicity, limited efficacy data, and restricted access, and evidence of its efficacy in conditions other than ENL awaits the results of controlled clinical trials. Expand
Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019
Patients who received hydroxychloroquine for the treatment of pneumonia associated with COVID-19 were at high risk of QTc prolongation, and concurrent treatment with azithromycin was associated with greater changes in QTC. Expand
Peginterferon alfa-2a: a review of approved and investigational uses.
The pharmacokinetic profile of IFN alfa-2a is improved by pegylation, which enables less frequent administration and results in improved efficacy with a similar side-effect profile. Expand
Clinically Significant Adverse Events from a Drug Interaction Between Quetiapine and Atazanavir‐Ritonavir in Two Patients
Clinicians caring for patients infected with the human immunodeficiency virus (HIV) and diagnosed with psychiatric comorbidities must be aware of potential drug‐drug interactions, particularly withExpand
Darunavir: a nonpeptidic antiretroviral protease inhibitor.
Darunavir has improved activity against resistant HIV isolates in patients with few treatment choices, particularly when enfuvirtide is added, and the safety profile of darunavIR is comparable to other protease inhibitors based on early data. Expand
Activity of fosfomycin and comparison of several susceptibility testing methods against contemporary urine isolates.
Support is lent to current guidelines that recommend fosfomycin as empirical first-line therapy for uncomplicated UTI by showing fairly consistent activity against a majority of isolates collected when using the susceptibility breakpoint of 64 μg/mL. Expand
Invitro Apramycin Activity against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa.
Apramycin appears to offer promising in vitro activity against highly resistant pathogens and may warrant further pre-clinical study to assess potential for repurposing as a human therapeutic and relevance as a scaffold for further medicinal chemistry exploration. Expand
Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence?
In patients treated with SoC antibiotics, BEZ is effective in decreasing rCDI, and the greatest benefit has been demonstrated in high-risk patients, though the targeted patient population is yet to be defined. Expand
Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis.
Drotrecogin alfa is the first adjunctive agent for the treatment of sepsis to display clinically and statistically significant effects on mortality rates at 28 days, and is offered a comprehensive review of the mechanism of action, pharmacokinetic profile, efficacy and safety profile, and pharmacoeconomics of drotrecog in alfa. Expand
Susceptibility of Multidrug-Resistant Gram-Negative Urine Isolates to Oral Antibiotics
Increasing resistance among Gram-negative uropathogens limits treatment options, and susceptibility data for multidrug-resistant isolates are limited, so empirical use of these agents likely provides inadequate coverage in areas with a high prevalence of multidrog-resistant uropATHogens. Expand